Frontiers in Immunology (May 2021)
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
- Patompong Satapornpong,
- Patompong Satapornpong,
- Patompong Satapornpong,
- Jirawat Pratoomwun,
- Jirawat Pratoomwun,
- Jirawat Pratoomwun,
- Pawinee Rerknimitr,
- Pawinee Rerknimitr,
- Jettanong Klaewsongkram,
- Jettanong Klaewsongkram,
- Jettanong Klaewsongkram,
- Nontaya Nakkam,
- Thanyada Rungrotmongkol,
- Thanyada Rungrotmongkol,
- Parinya Konyoung,
- Niwat Saksit,
- Ajanee Mahakkanukrauh,
- Warayuwadee Amornpinyo,
- Usanee Khunarkornsiri,
- Therdpong Tempark,
- Kittipong Wantavornprasert,
- Pimonpan Jinda,
- Pimonpan Jinda,
- Napatrupron Koomdee,
- Napatrupron Koomdee,
- Thawinee Jantararoungtong,
- Thawinee Jantararoungtong,
- Ticha Rerkpattanapipat,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Dean Naisbitt,
- Wichittra Tassaneeyakul,
- Manasalak Ariyachaipanich,
- Thapana Roonghiranwat,
- Munir Pirmohamed,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Chonlaphat Sukasem,
- Chonlaphat Sukasem,
- Chonlaphat Sukasem
Affiliations
- Patompong Satapornpong
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Patompong Satapornpong
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Patompong Satapornpong
- Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University, Pathum Thani, Thailand
- Jirawat Pratoomwun
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Jirawat Pratoomwun
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Jirawat Pratoomwun
- Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University, Samut Prakan, Thailand
- Pawinee Rerknimitr
- The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand
- Pawinee Rerknimitr
- Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Jettanong Klaewsongkram
- The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand
- Jettanong Klaewsongkram
- Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Jettanong Klaewsongkram
- King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
- Nontaya Nakkam
- Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- Thanyada Rungrotmongkol
- 0Biocatalyst and Environmental Biotechnology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand
- Thanyada Rungrotmongkol
- 1Program in Bioinformatics and Computational Biology, Graduated School, Chulalongkorn University, Bangkok, Thailand
- Parinya Konyoung
- 2Pharmacy Unit, Udon Thani Hospital, Udon Thani, Thailand
- Niwat Saksit
- 3Unit of Excellence on Pharmacogenomic Pharmacokinetic and Pharmacotherapeutic Researches (UPPER), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
- Ajanee Mahakkanukrauh
- 4Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- Warayuwadee Amornpinyo
- 5Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital, Khon Kaen, Thailand
- Usanee Khunarkornsiri
- 2Pharmacy Unit, Udon Thani Hospital, Udon Thani, Thailand
- Therdpong Tempark
- 6Division of Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Kittipong Wantavornprasert
- The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand
- Pimonpan Jinda
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Pimonpan Jinda
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Napatrupron Koomdee
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Napatrupron Koomdee
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Thawinee Jantararoungtong
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Thawinee Jantararoungtong
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Ticha Rerkpattanapipat
- 7Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Chuang-Wei Wang
- 8Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan
- Chuang-Wei Wang
- 9Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chuang-Wei Wang
- 0Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Dean Naisbitt
- 1Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom
- Wichittra Tassaneeyakul
- Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- Manasalak Ariyachaipanich
- 2Skin Center, Ruampaet Dr.ANAN Hospital, Surin, Thailand
- Thapana Roonghiranwat
- 3Department of Pediatrics, Prapokklao Hospital, Chantaburi, Thailand
- Munir Pirmohamed
- 1Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom
- Wen-Hung Chung
- 8Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan
- Wen-Hung Chung
- 9Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wen-Hung Chung
- 0Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Wen-Hung Chung
- 4Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
- Wen-Hung Chung
- 5Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chonlaphat Sukasem
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Chonlaphat Sukasem
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
- Chonlaphat Sukasem
- 6The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group, Bangkok, Thailand
- DOI
- https://doi.org/10.3389/fimmu.2021.661135
- Journal volume & issue
-
Vol. 12
Abstract
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10−7), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10−3), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10−5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10−7) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10−3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
Keywords
- dapsone-induced severe cutaneous adverse reactions
- HLA class I and II alleles
- HLA-B*13:01
- cytochrome P450
- Thais and Taiwaneses